Evidence-based oncology mitomycin C provides little additional benefit in the treatment of carcinoma of unknown primary site: Abstracted from: Assersohn L, Norman AR, Cunningham D et al. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer 2003; 39: 1121–1128